1. Home
  2. MIRM vs GRBK Comparison

MIRM vs GRBK Comparison

Compare MIRM & GRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • GRBK
  • Stock Information
  • Founded
  • MIRM 2018
  • GRBK N/A
  • Country
  • MIRM United States
  • GRBK United States
  • Employees
  • MIRM N/A
  • GRBK N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • GRBK Homebuilding
  • Sector
  • MIRM Health Care
  • GRBK Consumer Discretionary
  • Exchange
  • MIRM Nasdaq
  • GRBK Nasdaq
  • Market Cap
  • MIRM 3.3B
  • GRBK 2.9B
  • IPO Year
  • MIRM 2019
  • GRBK N/A
  • Fundamental
  • Price
  • MIRM $67.93
  • GRBK $69.20
  • Analyst Decision
  • MIRM Strong Buy
  • GRBK Buy
  • Analyst Count
  • MIRM 9
  • GRBK 2
  • Target Price
  • MIRM $73.89
  • GRBK $71.00
  • AVG Volume (30 Days)
  • MIRM 661.2K
  • GRBK 281.8K
  • Earning Date
  • MIRM 08-06-2025
  • GRBK 07-30-2025
  • Dividend Yield
  • MIRM N/A
  • GRBK N/A
  • EPS Growth
  • MIRM N/A
  • GRBK 7.68
  • EPS
  • MIRM N/A
  • GRBK 7.83
  • Revenue
  • MIRM $429,161,000.00
  • GRBK $2,137,742,000.00
  • Revenue This Year
  • MIRM $36.76
  • GRBK N/A
  • Revenue Next Year
  • MIRM $17.48
  • GRBK $12.17
  • P/E Ratio
  • MIRM N/A
  • GRBK $8.84
  • Revenue Growth
  • MIRM 62.33
  • GRBK 13.87
  • 52 Week Low
  • MIRM $36.86
  • GRBK $50.57
  • 52 Week High
  • MIRM $69.00
  • GRBK $84.66
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 82.95
  • GRBK 60.31
  • Support Level
  • MIRM $50.25
  • GRBK $63.46
  • Resistance Level
  • MIRM $67.45
  • GRBK $71.58
  • Average True Range (ATR)
  • MIRM 2.89
  • GRBK 2.12
  • MACD
  • MIRM 1.38
  • GRBK 0.48
  • Stochastic Oscillator
  • MIRM 94.29
  • GRBK 77.98

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About GRBK Green Brick Partners Inc.

Green Brick Partners Inc is a homebuilding and land development company. It acquires and develops land, as well as provides land and construction financing to its controlled builders. The company has three reportable segments: builder operations central, builder operations southeast, and land development. The majority of the company's revenue is generated from the builder operations central segment which is entirely the operations of builders in Texas. The company is engaged in various aspects of the homebuilding process, including land acquisition and development, entitlements, design, construction, marketing, sales, and brand image creation. In addition to homebuilding, the company provides home financing services, such as mortgage and title.

Share on Social Networks: